[EN] THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS<br/>[FR] THIÉNO[3,2-C]PYRIDIN-4(5H)-ONES UTILES COMME INHIBITEURS DE BET
申请人:GLAXOSMITHKLINE LLC
公开号:WO2014078257A1
公开(公告)日:2014-05-22
Thienopyridone compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
[EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
申请人:ALMIRALL SA
公开号:WO2014060431A1
公开(公告)日:2014-04-24
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
作者:Aranapakam M. Venkatesan、Christoph M. Dehnhardt、Zecheng Chen、Efren Delos Santos、Osvaldo Dos Santos、Matthew Bursavich、Adam M. Gilbert、John W. Ellingboe、Semiramis Ayral-Kaloustian、Gulnaz Khafizova、Natasja Brooijmans、Robert Mallon、Irwin Hollander、Larry Feldberg、Judy Lucas、Ker Yu、Jay Gibbons、Robert Abraham、Tarek S. Mansour
DOI:10.1016/j.bmcl.2009.11.057
日期:2010.1
This article describes the syntheses and SAR of a series of imidazolopyrimidine derivatives, which are evaluated as inhibitors of PI3-Kinase (PI3 K) and mTOR. These compounds were found to be ATP competitive with good tumor cell growth inhibition, and suppression of pathway specific biomakers such as phosphorylation of Akt at T308. (C) 2009 Elsevier Ltd. All rights reserved.
Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases
作者:Mariano A. E. Pinto-Bazurco Mendieta、Qingzhong Hu、Matthias Engel、Rolf W. Hartmann
DOI:10.1021/jm400484p
日期:2013.8.8
Dual CYP17/CYP11B2 inhibitors are proposed as a novel strategy for the treatment of prostate cancer to reduce risks of cardiovascular diseases. Via a combination of ligand- and structure-based approaches, a series of dual inhibitors were designed leading to the 2-(3-pyridyl)naphthalenes 10 and 11 with strong inhibition of both enzymes (IC50 values around 20 nM) and excellent selectivities over CYP11B1, CYP19, and CYP3A4. These compounds are considered as promising candidates for further in vivo evaluation.
Disrupting Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) Latent Replication with a Small Molecule Inhibitor
作者:Aylin Berwanger、Saskia C. Stein、Andreas M. Kany、Melissa Gartner、Brigitta Loretz、Claus-Michael Lehr、Anna K. H. Hirsch、Thomas F. Schulz、Martin Empting